TPST
Tempest Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Price History
Fundamentals
| Market Cap | $17.58M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.91 |
| EPS (TTM) | $-5.70 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -721.00% |
| Debt/Equity | 955.47 |
| Recommendation | None |
| Analyst Target | $11.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 28.0 |
| Beta | -1.78 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $12.23 |
| 52-Week Low | $1.02 |
| 50-Day Avg | $1.58 |
| 200-Day Avg | $4.10 |
| Avg Volume | 158.4K |
| Volume | 83.5K |
Performance Analysis
BULLISHTPST shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report